A Kaplan–Meier survival analysis revealed a superior outcome in DLBCL patients with a high CDCA2 expression when treated with RB-CHOP in comparison to R-CHOP (p = 0.012), whereas no difference in survival was observed for patients with low expression of CDCA2 (p = 0.095) (Figure 2A,B). The gene discussed is CDCA2; the disease is diffuse large B-cell lymphoma.